Institute for Clinical and Economic Review President Steven Pearson issued the following statement in response to President Donald Trump’s drug pricing speech:
“While encouraged to see both political parties evaluating new options to reform drug reimbursement, we continue to believe the fundamental challenge in the US pharmaceutical system is that — particularly in areas with little competition — a drug’s price rarely reflects the drug’s benefit for patients. There are times when our country receives tremendous value from medicine and other times when we’re getting ripped off, and our health care system struggles to tell the difference.
Outcomes-based and indication-specific contracting offer promise, as long as these novel arrangements are not positioned as a substitute for ensuring the drug’s underlying price is fairly aligned to its value.
We will continue to monitor these proposed federal reforms, as well as the accelerating efforts to better manage drug pricing by individual states and within the private market.”
For more information about ICER, visit their website by clicking here.